

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6669)

VOLUNTARY ANNOUNCEMENT

**MEMORANDUM OF UNDERSTANDING
IN RELATION TO PROPOSED COLLABORATIONS**

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business plan and development of the Group.

MEMORANDUM OF UNDERSTANDING

On June 15, 2023, the Company entered into a memorandum of understanding (the “**MOU**”) with Boston Scientific Group plc (“**BSG**”), pursuant to which Boston Scientific Corporation (“**BSC**”, together with its subsidiaries but excluding the Group, the “**BSC Group**”) and Group confirmed their mutual understanding that they intend to explore the opportunities to collaborate in several areas, including, among other things, research and development, manufacturing, and sales and marketing (collectively, the “**Collaborations**”). The Company and the BSC Group intend to explore the following areas of Collaborations by leveraging each party’s advantages on technology, technique, experience and resources, including:

- (a) enhancing research and development on cardiovascular diseases and developing products for markets including United States, China, Japan and European countries; developing products for the treatment of CTO (chronic total occlusion) lesions, lower extremity artery stenosis, varicose veins, access maintenance for dialysis patients and other areas;
- (b) manufacturing certain products on an OEM (original equipment manufacturer) basis for the other party to achieve cost efficiency;
- (c) cross selling or co-branding certain products in areas such as periphery, coronary artery, tumor, urinary, and andrology to maximize channel utilization and product value; and
- (d) supporting the registration of the other party’s products.

The terms and conditions of the Collaborations are subject to further negotiations between the parties thereof, which has not been finalized as at the date of this announcement.

LEGAL EFFECT

As agreed by the Company and BSG, the MOU does not constitute a legally binding agreement on the parties to the MOU. Nothing in the MOU imposes an obligation on either parties thereof to continue discussions or negotiations in connection with the Collaborations and either party thereof may, at its sole discretion, terminate discussions and negotiations with, the other party thereof at any time.

REASONS FOR AND BENEFITS OF THE MOU

After BSG became the controlling shareholder of the Company after completion of a voluntary conditional partial offer in February 2023, the Group and the BSC Group have been exploring commercial collaboration opportunities in R&D, manufacturing and commercialization to create synergistic value. The entering of the MOU will confirm their mutual understanding of such Collaborations.

GENERAL

This announcement is made by the Company on a voluntary basis.

BSG is the controlling shareholder of the Company, if the transactions contemplated under the Collaborations are materialized, such transactions contemplated may constitute connected transactions on the part of the Company pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Collaborations may or may not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the shares.

By Order of the Board
Acotec Scientific Holdings Limited
Jing LI

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, June 19, 2023

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.